Lantern Pharma Inc
LTRN5.191USD
+0.421+8.83%
Market hours （ET）Quotes delayed by 15 min
55.99MMarket Cap
LossP/E TTM
More Details of Lantern Pharma Inc Company
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Company Info
Ticker SymbolLTRN
Company nameLantern Pharma Inc
IPO dateJun 11, 2020
CEOMr. Panna L. Sharma
Number of employees24
Security typeOrdinary Share
Fiscal year-endJun 11
Address1920 Mckinney Avenue
CityDALLAS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code75201
Phone19722771136
Websitehttps://www.lanternpharma.com/
Ticker SymbolLTRN
IPO dateJun 11, 2020
CEOMr. Panna L. Sharma
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Jul 17
Updated: Thu, Jul 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
9.98%
Biological Mimetics, Inc
7.83%
Prophase Labs Inc
5.85%
The Vanguard Group, Inc.
3.37%
CM Management, LLC
1.85%
Other
71.12%
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
9.98%
Biological Mimetics, Inc
7.83%
Prophase Labs Inc
5.85%
The Vanguard Group, Inc.
3.37%
CM Management, LLC
1.85%
Other
71.12%
Shareholder Types
Shareholders
Proportion
Corporation
13.68%
Venture Capital
9.98%
Investment Advisor
7.67%
Investment Advisor/Hedge Fund
2.11%
Hedge Fund
1.29%
Individual Investor
0.42%
Research Firm
0.07%
Other
64.78%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
71
3.80M
35.21%
-556.52K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
2023Q2
72
4.61M
42.49%
-2.27M
2023Q1
73
4.92M
45.34%
-1.23M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bios Equity Partners, LP.
1.08M
9.98%
-157.85K
-12.79%
Jun 13, 2025
Biological Mimetics, Inc
844.13K
7.83%
-70.00K
-7.66%
Apr 15, 2025
Prophase Labs Inc
631.20K
5.85%
--
--
Apr 15, 2025
The Vanguard Group, Inc.
363.72K
3.37%
--
--
Mar 31, 2025
CM Management, LLC
200.00K
1.85%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
90.50K
0.84%
+3.53K
+4.06%
Mar 31, 2025
Renaissance Technologies LLC
88.80K
0.82%
+1.50K
+1.72%
Mar 31, 2025
GWM Advisors LLC
59.92K
0.56%
-8.44K
-12.34%
Mar 31, 2025
Voss Capital LLC
50.00K
0.46%
--
--
Mar 31, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.42%
+3.83K
+9.14%
Apr 15, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
